Cannabinoids and multiple sclerosis

Pharmacology and Therapeutics

Volumn 95, Issue 2, 2002, Pages 165-174

  Pertwee, Roger G ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Cannabis; Multiple sclerosis; Nabilone; Pain; Spinal cord injury; Tetrahydrocannabinol

Indexed keywords

CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; NABILONE; TETRAHYDROCANNABINOL;

ALLERGIC ENCEPHALOMYELITIS; ARTICLE; CLINICAL MEDICINE; DRUG BRAIN LEVEL; DRUG CONCENTRATION; DRUG EFFECT; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HYDROLYSIS; LITERATURE; MEMBRANE TRANSPORT; MULTIPLE SCLEROSIS; NOCTURIA; NONHUMAN; PAIN; PRIORITY JOURNAL; PUBLICATION; QUESTIONNAIRE; SPASTICITY; SPINAL CORD; SPINAL CORD INJURY; TREMOR;

EID: 0036669791     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0163-7258(02)00255-3     Document Type: Review

References (71)

1. Achiron A., Miron S., Lavie V., Margalit R., Biegon A. Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: implications for the treatment of acute relapses of multiple sclerosis. J Neuroimmunol. 102:2000;26-31.
2. 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev. 38:1986;21-43.
3. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Huffman J.W., Layward L. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 404:2000;84-87.
4. Baker D., Pryce G., Croxford J.L., Brown P., Pertwee R.G., Makriyannis A., Khanolkar A., Layward L., Fezza F., Bisogno T., Di Marzo V. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 15:2001;300-302.
5. 1 receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse. 41:2001;195-202.
6. Bouaboula M., Perrachon S., Milligan L., Canat X., Rinaldi-Carmona M., Portier M., Barth F., Calandra B., Pecceu F., Lupker J., Maffrand J.-P., Le Fur G., Casellas P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J Biol Chem. 272:1997;22330-22339.
7. 9-tetrahydrocannabinol on spasticity: a pilot study with 2 patients. Int J Clin Pharmacol Ther. 34:1996;446-452.
8. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
9. Clifford D.B. Tetrahydrocannabinol for tremor in multiple sclerosis. Ann Neurol. 13:1983;669-671.
10. Consroe P., Musty R., Rein J., Tillery W., Pertwee R. The perceived effects of smoked cannabis on patients with multiple sclerosis. Eur Neurol. 38:1997;44-48.
11. Coutts A.A., Brewster N., Ingram T., Razdan R.K., Pertwee R.G. Comparison of novel cannabinoid partial agonists and SR141716A in the guinea-pig small intestine. Br J Pharmacol. 129:2000;645-652.
12. Dunn M., Davis R. The perceived effects of marijuana on spinal cord injured males. Paraplegia. 12:1974;175.
13. Dyer O. Cannabis trial launched in patients with MS. Br Med J. 322:2001;192.
14. 2 receptors. Mol Pharmacol. 48:1995;443-450.
15. Fung M., Gallagher C., Machtay M. Lung and aero-digestive cancers in young marijuana smokers. Tumori. 85:1999;140-142.
16. Galiègue S., Mary S., Marchand J., Dussossoy D., Carrière D., Carayon P., Bouaboula M., Shire D., Le Fur G., Casellas P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur J Biochem. 232:1995;54-61.
17. Greenberg H.S., Werness S.A.S., Pugh J.E., Andrus R.O., Anderson D.J., Domino E.F. Short-term effects of smoking marijuana on balance in patients with multiple sclerosis and normal volunteers. Clin Pharmacol Ther. 55:1994;324-328.
18. Hamann W., di Vadi P.P. Analgesic effect of the cannabinoid analogue nabilone is not mediated by opioid receptors. Lancet. 353:1999;560.
19. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci. 11:1991;563-583.
20. Hodges C. I wish I could get it at the chemist's. The Independent. 1993, February 23.
21. Holdcroft A., Smith M., Jacklin A., Hodgson H., Smith B., Newton M., Evans F. Pain relief with oral cannabinoids in familial Mediterranean fever. Anaesthesia. 52:1997;483-488.
22. Hollister L.E. Health aspects of cannabis. Pharmacol Rev. 38:1986;1-20.
23. Howlett A.C., Fleming R.M. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol. 26:1984;532-538.
24. Jain A.K., Ryan J.R., McMahon F.G., Smith G. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. J Clin Pharmacol. 21(suppl. 8 & 9):1981;320S-326S.
25. Kearn C.S., Hillard C.J. A model for the study of cannabinoid actions in microglia. Abstracts of the 1999 Symposium on the Cannabinoids. 1999;44 International Cannabinoid Research Society, Burlington.
26. 9-Tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis. J Neuroimmunol. 23:1989;73-81.
27. 2 receptors. Br J Pharmacol. 124:1998;619-622.
28. Malec J., Harvey R.F., Cayner J.J. Cannabis effect on spasticity in spinal cord injury. Arch Phys Med Rehabil. 63:1982;116-118.
29. Martin B.R., Thomas B.F., Razdan R.K. Structural requirements for cannabinoid receptor probes. Pertwee R.G. Cannabinoid Receptors. 1995;35-85 Academic Press, London.
30. Martin R.S., Luong L.A., Welsh N.J., Eglen R.M., Martin G.R., MacLennan S.J. Effects of cannabinoid receptor agonists on neuronally-evoked contractions of urinary bladder tissues isolated from rat, mouse, pig, dog, monkey and human. Br J Pharmacol. 129:2000;1707-1715.
31. Martyn C.N., Illis L.S., Thom J. Nabilone in the treatment of multiple sclerosis. Lancet. 345:1995;579.
32. Maurer M., Henn V., Dittrich A., Hofmann A. Delta-9-tetrahydrocannabinol shows antispastic and analgesic effects in a single case double-blind trial. Eur Arch Psychiatry Clin Neurosci. 240:1990;1-4.
33. Mechoulam R. The pharmacohistory of Cannabis sativa. Mechoulam R. Cannabinoids as Therapeutic Agents. 1986;1-19 CRC Press, Boca Raton.
34. Meinck H.-M., Schönle P.W., Conrad B. Effect of cannabinoids on spasticity and ataxia in multiple sclerosis. J Neurol. 236:1989;120-122.
35. Molina-Holgado F., Molina-Holgado E., Guaza C. The endogenous cannabinoid anandamide potentiates interleukin-6 production by astrocytes infected with Theiler's murine encephalomyelitis virus by a receptor-mediated pathway. FEBS Lett. 433:1998;139-142.
36. Munro S., Thomas K.L., Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature. 365:1993;61-65.
37. Notcutt W., Price M., Blossfeldt P., Chapman G. Clinical experience of the synthetic cannabinoid nabilone for chronic pain. Nahas G.G., Sutin K.M., Harvey D., Agurell S. Marihuana and Medicine. 1999;567-572 Humana Press, Totowa. Ch. 47.
38. Noyes R., Brunk S.F., Avery D.H., Canter A. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther. 18:1975;84-89.
39. Noyes R., Brunk S.F., Baram D.A., Canter A. Analgesic effect of delta-9-tetrahydrocannabinol. J Clin Pharmacol. 15:1975;139-143.
40. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol. 54:1998;1064-1072.
41. Paton W.D.M., Pertwee R.G. The actions of cannabis in man. Mechoulam R. Marijuana. 1973;287-333 Academic Press, New York.
42. Pertwee R.G. The central neuropharmacology of psychotropic cannabinoids. Pharmacol Ther. 36:1988;189-261.
43. Pertwee R.G. In vivo interactions between psychotropic cannabinoids and other drugs involving central and peripheral neurochemical mediators. Murphy L., Bartke A. Marijuana/Cannabinoids. Neurobiology and Neurophysiology. 1992;165-218 CRC Press, Boca Raton.
44. 2 receptors. Pharmacol Ther. 74:1997;129-180.
45. Pertwee R.G. Cannabinoid receptor ligands: clinical and neuropharmacological considerations, relevant to future drug discovery and development. Expert Opin Invest Drugs. 9:2000;1553-1571.
46. Pertwee R.G. Cannabinoid receptors and pain. Prog Neurobiol. 63:2001;569-611.
47. 1 receptors in mouse urinary bladder. Br J Pharmacol. 118:1996;2053-2058.
48. Pertwee R.G., Greentree S.G. Delta-9-tetrahydrocannabinol-induced catalepsy in mice is enhanced by pretreatment with flurazepam or chlordiazepoxide. Neuropharmacology. 27:1988;485-491.
49. Pertwee R.G., Wickens A.P. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology. 30:1991;237-244.
50. Pertwee R.G., Greentree S.G., Swift P.A. Drugs which stimulate or facilitate central GABAergic transmission interact synergistically with delta-9-tetrahydrocannabinol to produce marked catalepsy in mice. Neuropharmacology. 27:1988;1265-1270.
51. Pertwee R.G., Gibson T.M., Stevenson L.A., Ross R.A., Banner W.K., Saha B., Razdan R.K., Martin B.R. O-1057, a potent water-soluble cannabinoid receptor agonist with antinociceptive properties. Br J Pharmacol. 129:2000;1577-1584.
52. 9-tetrahydrocannabinol. J Clin Pharmacol. 21(suppl. 8 & 9):1981;413S-416S.
53. Portier M., Rinaldi-Carmona M., Pecceu F., Combes T., Poinot-Chazel C., Calandra B., Barth F., Le Fur G., Casellas P. SR 144528, an antagonist for the peripheral cannabinoid receptor that behaves as an inverse agonist. J Pharmacol Exp Ther. 288:1999;582-589.
54. Razdan R.K. Structure-activity relationships in cannabinoids. Pharmacol Rev. 38:1986;75-149.
55. Richter A., Löscher W. (+)-WIN 55,212-2, a novel cannabinoid receptor agonist, exerts antidystonic effects in mutant dystonic hamsters. Eur J Pharmacol. 264:1994;371-377.
56. Rinaldi-Carmona M., Barth F., Millan J., Derocq J.-M., Casellas P., Congy C., Oustric D., Sarran M., Bouaboula M., Calandra B., Portier M., Shire D., Brelière J.-C., Le Fur G. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J Pharmacol Exp Ther. 284:1998;644-650.
57. Rodriguez M., Pavelko K.D., McKinney C.W., Leibowitz J.L. Recombinant human IL-6 suppresses demyelination in a viral model of multiple sclerosis. J Immunol. 153:1994;3811-3821.
58. 8-tetrahydrocannabinol at cannabinoid receptors. Br J Pharmacol. 128:1999;735-743.
59. Schnelle M., Grotenhermen F., Reif M., Gorter R.W. Results of a standardized survey on the medical use of cannabis products in the German-speaking area. Forsch Komplementärmed. 6(suppl. 3):1999;28-36.
60. Schon F., Hart P.E., Hodgson T.L., Pambakian A.L.M., Ruprah M., Williamson E.M., Kennard C. Suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis. Neurology. 53:1999;2209-2210.
61. Sherman M.P., Campbell L.A., Gong H., Roth M.D., Tashkin D.P. Antimicrobial and respiratory burst characteristics of pulmonary alveolar macrophages recovered from smokers of marijuana alone, smokers of tobacco alone, smokers of marijuana and tobacco, and nonsmokers. Am Rev Respir Dis. 144:1991;1351-1356.
62. Sim-Selley L.J., Brunk L.K., Selley D.E. Inhibitory effects of SR141716A on G-protein activation in rat brain. Eur J Pharmacol. 414:2001;135-143.
63. Slipetz D.M., O'Neill G.P., Favreau L., Dufresne C., Gallant M., Gareau Y., Guay D., Labelle M., Metters K.M. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol. 48:1995;352-361.
64. Tramposch A., Sangdee C., Franz D.N., Karler R., Turkanis S.A. Cannabinoid-induced enhancement and depression of cat monosynaptic reflexes. Neuropharmacology. 20:1981;617-621.
65. 9-tetrahydrocannabinol on cat spinal motoneurons. Brain Res. 288:1983;283-287.
66. Turkanis S.A., Karler R. Cannabidiol-caused depression of spinal motoneuron responses in cats. Pharmacol Biochem Behav. 25:1986;89-94.
67. Ungerleider J.T., Andyrsiak T., Fairbanks L., Ellison G.W., Myers L.W. Delta-9-THC in the treatment of spasticity associated with multiple sclerosis. Adv Alcohol Subst Abuse. 7:1987;39-50.
68. Van der Kloot W. Anandamide, a naturally-occurring agonist of the cannabinoid receptor, blocks adenylate cyclase at the frog neuromuscular junction. Brain Res. 649:1994;181-184.
69. Welch S.P., Stevens D.L. Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther. 262:1992;10-18.
70. Whittle B.A., Guy G.W., Robson P. Prospects for new cannabis-based prescription medicines. J Cannabis Ther. 1:2001;183-205.
71. Wirguin I., Mechoulam R., Breuer A., Schezen E., Weidenfeld J., Brenner T. Suppression of experimental autoimmune encephalomyelitis by cannabinoids. Immunopharmacology. 28:1994;209-214.